Introduction:Using nasal continuous positive airway pressure (CPAP) for neonatal respiratory support is highly increasing in low and middle-income countries. It reduces the needs for mechanical ventilation in neonates with respiratory distress (RD) in tertiary hospitals. Objectives:This is a prospective non-randomized study aims to evaluate the role and efficiency of bubble CPAP in treatment of neonatal respiratory distress and correlation of bubble CPAP failure with different studied demographic, clinical and laboratory variable data. Patients and methods: The study included all neonates with respiratory distress admitted to neonatal intensive care unit (NICU)-Minia University hospital from 1st of January to 31st of December 2017.The study analyzed the rate of failure and response of management of those patients on bubble CPAP and compared them with other different treatment modalities according to variable recorded demographic, clinical and laboratory data. Results: Among the 280 cases, 149 patients (53.2%) were treated with oxygen, 52 patients (18.6%) needed to be treated with bubble CPAP, 79 patients (28.2%) needed to be intubated and mechanically ventilated (MV). Our study showed more incidences of bubble CPAP therapy of RD cases with higher gestational ages and birth weight, milder grades of RD, absence of sepsis in comparison with mechanical ventilation and vice versa for comparison with nasal oxygen therapy. Conclusion:CPAP is an effective treatment of RD leading to significant improvement of outcome reducing hospital stay, need for invasive mechanical ventilation with its harmful adverse effects and thus the case fatality rate of RD cases and so the overall mortality rate of the NICU.

No abstract

No abstract

Objectives:We tested the effects of BTA injections in septum ,middle and inferior turbinates, on patients who had AR for a minimum of three years and had been treated unsuccessfully with conventional medications. Method: The study was an interventional case-control single-blind randomized clinical trial . 20 male and female AR patients who were referred to the hospital of Minya university ,in 2019; aged 15-52 years were selected on the basis of inclusion and exclusion criteria. The subjects were randomly assigned to the intervention (n=10) or control group (n=10). The intervention group received BTA (45 IU/ml; medytox), by injection intranasally in septum , middle and inferior turbinates. The control group received normal saline. The groups were evaluated by the same examiner. post-tests (1,4, and 12 weeks) were performed according to the authors' pre-designed checklist, the validity and reliability of which was previously established. The symptoms scored from none (0) to severe (10) at the test points. The statistical analysis was conducted with SPSS-19, with a significance level of 0.05. Results: Based on ANOVA, there was a significant difference (P<0.05) in symptomatic relief between the intervention and control groups. No marked adverse effects were observed during the study. Discussion: An intranasal injection of BTA, , may alleviate AR symptoms with no significant adverse effects.

No abstract